Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Uni-Ranibizumab
- Development stage
- Preclinical
- Lead developer
- Uni-Bio Science
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Ophthalmic
01
Overview
Uni-Ranibizumab is a biosimilar candidate of the monoclonal antibody fragment ranibizumab, currently under development by Uni-Bio Science Group. As an anti-vascular endothelial growth factor (VEGF) biologic, it is specifically engineered to target and neutralize VEGF-A, a protein that promotes the growth of abnormal, leaky blood vessels in the retina. By inhibiting the signaling pathway of VEGF-A, Uni-Ranibizumab aims to treat neovascular (wet) age-related macular degeneration (wAMD) and other retinal vascular disorders such as diabetic macular edema (DME) and retinal vein occlusion (RVO). The drug is designed for intravitreal administration, providing a localized therapeutic effect to stabilize or improve vision by reducing pathological angiogenesis and macular edema. It is currently in the pre-clinical and IND-enabling stages of development.
- Other names
- anti-VEGF biologicranibizumab biosimilaranti-VEGF antibody
02
Targets
Beyond the preview
Go deeper on Uni-Ranibizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Uni-Ranibizumab.